| Autor: |
Long J; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544., Mariossi A; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544., Cao C; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544., Mo Z; Bristol Myers Squibb, San Diego, CA 92121., Thompson JW; Bristol Myers Squibb, San Diego, CA 92121., Levine MS; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544.; Department of Molecular Biology, Princeton University, Princeton, NJ 08544., Lemaire LA; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544.; Department of Biology, Saint Louis University, St. Louis, MO 63103. |
| Abstrakt: |
Thalidomide has a dark history as a teratogen, but in recent years, its derivates have been shown to function as potent chemotherapeutic agents. These drugs bind cereblon (CRBN), the substrate receptor of an E3 ubiquitin ligase complex, and modify its degradation targets. Despite these insights, remarkably little is known about the normal function of cereblon in development. Here, we employ Ciona , a simple invertebrate chordate, to identify endogenous Crbn targets. In Ciona, Crbn is specifically expressed in developing muscles during tail elongation before they acquire contractile activity. Crbn expression is activated by Mrf, the ortholog of MYOD1, a transcription factor important for muscle differentiation. CRISPR/Cas9-mediated mutations of Crbn lead to precocious onset of muscle contractions. By contrast, overexpression of Crbn delays contractions and is associated with decreased expression of contractile protein genes such as troponin. This reduction is possibly due to reduced Mrf protein levels without altering Mrf mRNA levels. Our findings suggest that Mrf and Crbn form a negative feedback loop to control the precision of muscle differentiation during tail elongation. |
